ONVO - Organovo Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Organovo Holdings, Inc.

6275 Nancy Ridge Drive
Suite 110
San Diego, CA 92121
United States

IndustryDiagnostics & Research
Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Mr. Taylor J. CrouchCEO, Pres & Director751.38kN/A1960
Mr. Craig KussmanChief Financial Officer549.2kN/A1959
Ms. Jennifer Kinsbruner BushSr. VP, Gen. Counsel, Corp. Sec. & Compliance Officer506.44kN/A1975
Mr. Steve E. KunszaboVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it is involved in various programs to develop its NovoTissues to address various serious unmet medical needs primarily focusing on liver disease. Organovo Holdings, Inc. has a collaboration agreement with Murdoch Children's Research Institute, The Royal Children's Hospital, and Leiden University Medical Center to develop stem cell-based bioprinted tissue treatments for kidney disease.s The company was founded in 2007 and is headquartered in San Diego, California.

Corporate Governance

Organovo Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.